EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RDEA study supports development of new NNRTI



RDEA study supports development of new NNRTI



Project Inform Perspective: 11-12




(PDF emailed within 1 workday: $29.90)

Accession: 055333969

Download citation: RISBibTeXText

PMID: 19230233



Related references

Evidence that the RdeA protein is a component of a multistep phosphorelay modulating rate of development in Dictyostelium. Embo Journal 17(10): 2809-2816, 1998

Emergence of an NNRTI resistance mutation Y181C in an HIV-infected NNRTI-naive patient. Aids Research and Human Retroviruses 24(3): 413-415, 2008

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. Aids 17(18): F49-F54, 2003

Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. Journal of Clinical Laboratory Analysis 16(2): 76-78, 2002

Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clinical Therapeutics 31(4): 692-704, 2009

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrobial Agents and ChemoTherapy 54(2): 718-727, 2010

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. HIV Medicine 13(1): 62-72, 2012

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients. HIV Clinical Trials 3(1): 36-44, 2002

TMC120 , a next generation NNRTI, has potent in vitro activity against NNRTI resistant HIV variants including recombinant clinical isolates. Antiviral Research 50(1): A41, April, 2001

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. Antiviral Therapy 8(5): 395-402, 2003

In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1. Journal of Virology 80(9): 4440-4446, 2006

Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial. HIV Clinical Trials 15(5): 209-217, 2014

Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy naive subjects. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 311, 2000

Differences in duration of therapy and viral suppression rates in different therapy sequencing scenarios PI to NNRTI vs NNRTI to PI. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 327, 2000

The RdeA-RegA system, a eukaryotic phospho-relay controlling cAMP breakdown. Journal of Biological Chemistry 274(39): 27379-27384, 1999